New Options for Transplant-Ineligible or Deferred Multiple Myeloma Patients: Recent Trial Insights image

New Options for Transplant-Ineligible or Deferred Multiple Myeloma Patients: Recent Trial Insights

Feb 11, 2025
11:00AM - 12:00PM EST
Online Event
Overview

Join us for an insightful webinar featuring Dr. Marc Braunstein as he delves into the groundbreaking results of the CEPHEUS trial, focusing on treatment for newly diagnosed multiple myeloma patients who are transplant-ineligible or deferred. Discover what these findings mean for the future of multiple myeloma care and how they could reshape treatment strategies. Don’t miss this opportunity to gain expert insights and ask your questions live!

 

Highlights
Agenda
11:00 AM
Introductions
Cynthia Cahoon, RN

Cynthia introduces the agenda of the event and featured speaker Dr. Marc Braunstein

11:05 AM
Presentation
Marc Braunstein, MD, PhD
 

Join Dr. Marc Braunstein explores CEPHEUS trial results, advancing care for transplant-ineligible multiple myeloma patients.

11:35 AM
Questions and Answers
Audience

Type your questions in the chat and we will answer them! 

Speakers & Moderators
Healthtree contact Cynthia Cahoon, RN

Cynthia Cahoon, RN

Cynthia is a newborn ICU nurse by trade that has spent the last six years in the medical device industry educating nurses and doctors about devices that are new to their facility. In her spare time she enjoys hiking, traveling the world with her family, and creating Halloween animatronics for her annual front yard display. She has a passion for life-long learning and enjoys sharing what she learns with the people around her.

Healthtree contact Marc Braunstein, MD, PhD

Marc Braunstein, MD, PhD

Marc Braunstein, MD, PhD is a board-certified hematologist/oncologist with a long-standing interest in plasma cell disorders. He is a part of the NYU Perlmutter Cancer Center's multiple myeloma and cellular therapy programs and serve as Associate Professor of Medicine at NYU Grossman Long Island School of Medicine where he co-direct the medical school hematology curriculum and also serves as Director of the hematology/oncology fellowship program. His clinical research focus is on the use of novel immunotherapy combinations to treat multiple myeloma. As part of his role, he also focuses on medical education and serves on education committees for the American Society of Hematology and American Society of Clinical Oncology, as well as volunteer committees with the American Society of Clinical Oncology and American College of Physicians. In his free time he volunteers with the Leukemia and Lymphoma Society, spends time with his family, and enjoys playing guitar and mandolin.